Member Info for Orange88

The £100k @ 7.20 is a certain buy, the others less clear cut. The bid jumped very suddenly yesterday morning and it makes a lot more sense now. Now this huge order has been filled and publicised, the SP could really motor!

Hi Degsy, Strongly agree with this. The way the two significant trades this morning increased the price illustrated how small the free float is here and any sustained buy volume will hike the price up. Further to your point on the board recommending the financing, there is also the following fact in the last RNS; ‘In addition, the Directors of IIP confirm that they have received an irrevocable undertaking to vote in favour of the Resolution from GGIC IIP Holdings, Ltd. in respect of 175,324,980 Ordinary Shares, representing 25.77 per cent. of the Company's issued ordinary share capital.’ This, plus the 2 x £20k director buys on 31st July gave me a lot more confidence that the deal will be approved. In summary, the investment has the potential to be transformational for IIP ‘Significantly, the partnership with PSA, which is one of the leading global port groups with significant port operations across Asia, Europe and the Americas, which would result from the Proposed Financing will provide DLI with the additional expertise and know-how of an established global platform and enhanced marketing opportunities.’ Fingers crossed things play out smoothly!

Hi cminhinnett, apologies I didn’t see the reply to my original post. I’ve tried to explain my point below; The original H1 2017 figures included significant low margin revenue, from the RNS datesd 31/07/17, gross revenue was £10.5m, from which ‘commissions’ of £4.5m were then deducted, leaving net revenue of £6m. In the restated accounts there is no comissions figure for H1 2018, so it is my assumption that this cost was directly associated with the low margin product that was cancelled. So, yes they are presented on a comparable basis, but the H1 2017 numbers include at least £4.5m of now discontinued low margin revenue. Had this low margin revenue been retained, we would have reported total revenue including commission share of at least £13.9m for H1 2018, and revenue of £9.4m; an increase of £3.4m/57% on H1 2017. The problem is that none of this is explicitly stated in the H1 2018update, if the following sentence had included the amount of revenue involved, investors would have had much more clarity; ‘The decline is due to the Company terminating a low margin advertising revenue product in the first quarter of 2017.’ In summary, I believe BBSN is performing significantly better than the comparative numbers show. The H2 figures should truly show this, as the low margin product will not interfere. The cynic in me thinks that the IFRS 15 rule change provided the perfect opportunity to disguise net revenue performance and buy more time to cement the turnaround - time will tell! All in my opinion, DYOR

Decent sized sell showing on Nex at 1.36 which somewhat explains why the ask didn’t rise at the time. Must be a larger sell being filled in the background as well though. 06/08/2018 15:07 141,345 1.49 06/08/2018 13:36 268,608 1.426 06/08/2018 13:14 57,193 1.46 Following the 400% rise on partnership news in Dec 17, the business has released a very positive trading update, multiple distribution agreements & raised enough cash to last at least 2 years, yet finds itself trading below cash value... a buy and hold until at least the end of H2 2018 has the potential to provide significant upside IMO.

We are unfortunate that the IFRS 15 contract revenue restatement to gross up both revenue and costs has partially obscured a very good H1 result. Reported net revenue in H1 2017 was £6m, which was after a commission share of £4.5m was paid, this has now been grossed up to £10.5m. So in reality, we have seen net revenue growth of circa 55%. I am very frustrated that this hasn’t been made clearer in the RNS! Nevertheless, very good progress on the road to breakeven, and our cash balance remains solid with only £700k outflow in H1. I just hope new and existing investors aren’t misled by the false fall in net revenue, and the lack of clarity on margins etc. It’s a lot better than the headline figures show!

Why would that have any impact on the current price? It’s not as if she is going to start offloading her stake... Need to look at the bigger picture here!

Brainer, can you explain why you were ramping Okyo Pharma to high heaven last weekend (a pump which has a mcap of 28m that appears to have no justification at all), yet are so scathing of IMTK? Smacks of jealousy to me. IMTK looks a bargain at this price and I’ll be buying in Monday morning - huge potential upside!

From the outside looking in, it seems as if Tlou’s future is reliant on the Botswanan government choosing it over a local company... The other company being invited to re-tender is a local Botswana company Sekaname (PTY) Ltd. Surely until this tender is granted this is about as a big a gamble as you could find?

Hi Vitali, Great post as always! Following on from this I did some very brief research and found the following article dated 13th July that states one publisher expects to make $10m from the ad breaks program in 2018 and several publishers over $1m. Unclear if this article could relate to BB or is just US domiciled publishers, but shows the potential as you say... https://digiday.com/media/facebook-video-ad-breaks-signs-of-life/ Furthermore, page 5 of our 2017 annual report has the following quote; ‘Our Q4 platform advertising revenues benefitted heavily from our entry to the Facebook ‘ad breaks’ beta testing.’ There is no breakdown of how much revenue was actually generated via ad breaks in Q4, but the above comment suggests it could have been material, as in a few hundred thousand at least? As such I’m very intrigued to discover the H1 revenues given the spectacular viewing figures achieved. The Digiday article adds even more intrigue, we can but hope the numbers deliver!

Definitely seem to have formed a solid base at 1.50 and is now starting to build :) Big thanks to all of the thoughtful discussion below this week, hopefully help bring some new investors on board before the interims. Another positive that I haven’t seen discussed is the fact they cancelled a £2m overdraft facility in Feb 18 as it was deemed unnneccessary due to their cash position - got to mean breakeven was very close!

Advertised spread of 22% is crazy, actual spread currently 1.755 - 1.86 and slowly narrowing. Interesting times ahead I feel.

Terrific news, the ability to attract industry leading figures illustrates we are going places IMO. This also seems to prove that yesterday’s sudden surge of buying wasn’t down to technicals, but more the fact this news leaked...

Wow, thanks for that insightful contribution such! There hasn’t been any ramping in here, merely stating that those who have patience will stand much more chance of making money here. @Vitali, I’ve also got just over 200k shares and intend to hold for the foreseeable. BBSN was at 5p two years ago and there have been no placings since then, the business strategy is starting to bear fruit & we have a great CEO & CFO who have a track record of success. All that’s needed is a medium term hold and if you’ve done your research, it’s much easier to do so!

I think releasing a positive RNS and folllowing it up with a discounted placing is a great way to alienate any new shareholders that had been spiked! Great news and a very refreshing was of releasing it - no negatives as far as I can see, especially with a director buy of that size!

Was just thinking the exact same thing! It’s not been near that market cap since August 17.

Very positive end to the week - was that you topping up ready for Monday Daveavt? Enjoy your weekend of spouting negative nonsense in here ;)

The key message from the video is that momentum is strong; a snowball effect trieggered by the Merck agreement. I also like the fact that Dr Jim Millen was a deal closing specialist prior to leaving big pharma for PYC - it’s clear these skills are playing a part in the step change in new business. The bottom line is that this company is doing its utmost to assist in the battle against cancer, and has performed very strongly over the past 6 months, both in share price and business development. These are undisputable facts, and in my opinion there is a long way to go here.

Applegarth, glad to provide some support and positivity! I can’t think why anyone would write so many negative posts every day over a period of months unless they were being paid to do so, or had a vendetta against the company. Potnak, if your cut and paste scenario came true and PYC had revenues of 2m, that would be an increase of over 7x year on year and undoubtedly see them turn a decent profit. Time will tell, but given the step change in activity post finalising the Merck Master Services Agreement combined with industry trends towards personalised medicines, I think the furtive looks very bright.

Prior to the November announcement, the PYC market cap was around £500k, and as the agreement with Merck is worth €500k per annum, it was no surprise that the share price went crazy. Since then, on 26th Jan and 9th Feb PYC have announced they have commenced projects for 35k and 70k with a major pharma and a global top 10 pharma, who are unnamed at present. PYC have a validated business model, do not obviously require funding, are working with two top 10 global pharma’s, and have a market cap of £3.9m. Any argument as to whether the share price should be 3p, 4p 5p or less is irrelevant unless you are a short term trader or shorter. If you have a time horizon of >6months the potential upside here is far greater, and as such a 5% allocation in my portfolio is a no brainer. Re the 2014 RNS announcing Merck as a partner, how much of this news was priced in with the market cap at 500k? My opinion; absolutely none of it.

Prior to the November announcement, the PYC market cap was around £500k, and as the agreement with Merck is worth €500k per annum, it was no surprise that the share price went crazy. Since then, on 26th Jan and 9th Feb PYC have announced they have commenced projects for 35k and 70k with a major pharma and a global top 10 pharma, who are unnamed at present. PYC have a validated business model, do not obviously require funding, are working with two top 10 global pharma’s, and have a market cap of £3.9m. Any argument as to whether the share price should be 3p, 4p 5p or less is irrelevant unless you are a short term trader or shorter. If you have a time horizon of >6months the potential upside here is far greater, and as such a 5% allocation in my portfolio is a no brainer. Re the 2014 RNS announcing Merck as a partner, how much of this news was priced in with the market cap at 500k? My opinion; absolutely none of it.